ACRS Earnings — Aclaris Therapeutics, Inc. Post-ER Performance | BigEarnings
ACRS — Aclaris Therapeutics, Inc.
XNAS · Healthcare · Biotechnology
Price$4.55
Market Cap$635.5M
P/E—
52W Range$1.34 – $5.15
Next Earnings2026-08-06
About Aclaris Therapeutics, Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.
